Biologic Treatments for Moderate to Severe Atopic Dermatitis

>

Latest News

Advancements in Understanding the Skin's Microbiomes
Advancements in Understanding the Skin's Microbiomes

March 20th 2023

Adam Friedman, MD, FAAD, offers highlights from his session at AAD 2023 on how cutaneous dysbiosis plays a role in some common skin conditions.

Dupilumab Treatment Improves Sleep Quality in Moderate-to-Severe AD in Children and Their Caregivers
Dupilumab Treatment Improves Sleep Quality in Moderate-to-Severe AD in Children and Their Caregivers

July 7th 2022

FDA grants priority review for dupilumab in pediatric AD
FDA grants priority review for dupilumab in pediatric AD

January 31st 2020

Tralokinumab meets endpoints for all phase 3 studies
Tralokinumab meets endpoints for all phase 3 studies

December 16th 2019

Fast Track designation granted to lebrikizumab for atopic dermatitis
Fast Track designation granted to lebrikizumab for atopic dermatitis

December 11th 2019

© 2024 MJH Life Sciences

All rights reserved.